
Acute myelomonocytic leukemia (AML) with KMT2A::MLLT3 translocation comprises two distinct subtypes: one linked to MECOM oncogene expression, older age, and poor outcomes, and another seen in younger patients with favorable prognosis but without MECOM. Bioinformatic analysis revealed HMX3, a neuronal transcription factor, as a key determinant in the MECOM-negative group. HMX3 was highly expressed in younger patients and specific to KMT2A-rearranged and KAT6A-CREBBP leukemias (p < 0.00001). Functional assays showed that forced HMX3 expression in healthy CD34+ cells drove E2F and MYC oncogenic pathways (p < 0.001) and blocked monocytic differentiation. Silencing HMX3 in KMT2A::MLLT3 cells induced cell cycle arrest, monocytic differentiation, and apoptosis. The identifies HMX3 as a leukemia-specific vulnerability and a potential therapeutic target in MECOM-negative KMT2A::MLLT3 AML.
Like
Save
Share